None

Revumenib-REVUFORJ is a new oral targeted drug mainly used to treat patients with acute myeloid leukemia (AML) with NPM1 or KMT2A gene rearrangements. By inhibiting key oncogenic signaling pathways, it prevents leukemia cell proliferation and induces apoptosis, making it an important targeted treatment option for AML patients with specific gene mutations. Due to its strong targeting and clear clinical efficacy, it has become a new treatment hope for patients with refractory or relapsed AML.

In terms of drug launch and drug purchase channels, Revimenib is not currently available in the country, so domestic patients cannot purchase it directly through hospitals or pharmacies. For patients who are in urgent need of medication, they can obtain the US version of the original drug through regular overseas channels. The American version of Revimenib is available in two specifications: 110 mg 30 tablets and 160 mg 30 tablets. Each box is priced at about 200,000 yuan. It is expensive and must comply with international prescription drug management regulations, including providing legal prescriptions and medical certificates to ensure the legal source and safe use of the drug.

Generic versions of Revemenib have appeared in overseas markets. The ingredients of these generic drugs are basically the same as those of the original drug, but the price is significantly lower than the US version of the original drug. For example, the generic drugs produced by Lucius in Laos are priced at approximately RMB 6,200 per box of 110 mg 30 tablets, and approximately RMB 8,300 per box of 160 mg 30 tablets, which greatly reduces the cost of drug purchase for patients. When obtaining generic drugs through formal overseas drug purchase channels, you also need to follow international prescription drug and cross-border transportation regulations to ensure drug safety and quality.

In clinical use, whether it is an original drug or a generic drug, patients should undergo individualized dose adjustment and treatment course management under the guidance of a professional doctor. During use, blood, liver and kidney function and possible adverse reactions need to be monitored regularly to ensure efficacy and safety. At the same time, patients and their families should understand the source and usage specifications of drugs and avoid obtaining drugs through informal channels to ensure the legality, effectiveness and safety of treatment and achieve the best clinical benefits.
Keyword tags: revimenib, acute myeloid leukemia, NPM1/KMT2A mutation, targeted therapy, generic drugs
Reference: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215891s000lbl.pdf